Ultram
Ultram
Generic Name
Ultram
Brand Names
for tramadol hydrochloride) is a synthetic opioid analgesic that modulates pain through a dual mechanism of action.
Mechanism
- Partial μ‑opioid receptor agonist – provides analgesia by inhibiting nociceptive signal transmission in the CNS.
- Inhibition of serotonin and norepinephrine reuptake – enhances descending inhibitory pain pathways and augments opioid effect.
- The combination yields moderate analgesic potency with a lower risk of tolerance compared to pure μ‑agonists.
Pharmacokinetics
- Administration: Oral (tablet, capsule, liquid), IV (rare), subcutaneous (rare).
- Absorption: Rapid; peak plasma concentration (Tmax) 1–2 h post‑dose.
- Bioavailability: ~66 % (oral); IV = 100 %.
- Distribution: Extensive; volume of distribution (Vd) ~1 L/kg; highly protein‑bound (~80 %).
- Metabolism: Hepatic via CYP2D6 → O‑desmethyltramadol (active metabolite); secondary CYP3A4 → N‑desmethyltramadol (inactive).
- Poor CYP2D6 metabolizers: ↓ analgesia; ultra‑rapid metabolizers: ↑ risk of adverse effects.
- Elimination: Renal (≈50 % unchanged; 30 % as metabolites).
- T1/2: 3–4 h (tramadol), 7–9 h (O‑desmethyltramadol).
Indications
- Acute pain: Post‑operative, dental, trauma, musculoskeletal injuries.
- Chronic non‑cancer pain: Osteoarthritis, neuropathic pain (when other agents inadequate).
- Relief of breakthrough pain in patients already on chronic opioid therapy.
Contraindications
- Absolute Contraindications:
- Known hypersensitivity to tramadol or any excipients.
- Severe respiratory depression or untreated severe asthma.
- Severe hepatic or renal impairment (dose adjustment required).
- Concurrent use with monoamine oxidase inhibitors (MAOIs).
- Precautions:
- Elderly patients; risk of falls, sedation, respiratory depression.
- Pregnant & lactating women (Category C).
- Concomitant serotonergic agents → risk of serotonin syndrome.
- Drug Interactions:
- SSRIs, SNRIs, MAOIs, fenfluramine, linezolid, carbamazepine, phenytoin → ↑ tramadol levels.
- NSAIDs, SSRIs → ↑ bleeding risk.
Dosing
| Population | Dosage Regimen | Max Daily Dose |
| Adults | 50 mg orally every 6–8 h as needed | 400 mg/day |
| Elderly (≥65 yr) | 25–50 mg q6‑8 h | 400 mg/day |
| Pediatric (≥12 yr) | 0.5–1 mg/kg q6‑8 h | 400 mg/day (adjust for weight) |
| Key | Initial dose may be low if susceptible to respiratory depression. | Taper gradually to avoid withdrawal. |
• Formulations: Tablet, capsule, oral suspension, IV infusion (1.5 mg/kg/h).
• Administration tips: Take after meals to reduce nausea; avoid alcohol.
Adverse Effects
| Category | Adverse Effects |
| Common | Nausea, dizziness, constipation, headache, somnolence, dry mouth, fatigue, low‑grade hyperalgesia. |
| Serious | Opioid‑related: respiratory depression, sedation, QT prolongation, serotonin syndrome (with serotonergic drugs), seizures (especially in CYP2D6 ultra‑rapid metabolizers). |
| Withdrawal | Irritability, anxiety, tremor, nausea. |
Monitoring
- Vital Signs: Respiratory rate, oxygen saturation, level of consciousness (especially in the first 24 h of therapy or after dose increase).
- Laboratory: Renal function (CrCl), hepatic panels if prolonged use.
- ECG: QT interval if concomitant QT‑prolonging agents.
- Patient‑Reported: Pain score, sedation level, nausea.
- Screen for Serotonin Syndrome: agitation, autonomic instability, neuromuscular abnormalities when combined with serotonergic drugs.
Clinical Pearls
- CYP2D6 Genotyping Matters:
- Poor metabolizers: Provide alternative analgesics (e.g., NSAIDs, scheduled opioids).
- Ultra‑rapid metabolizers: Consider lower dose and monitor for seizures/over‑analgesia.
- Avoid Abrupt Discontinuation:
- Use a gradual taper to prevent withdrawal symptoms; consider bridging agent like gabapentin for neuropathic pain.
- Pregnancy & Lactation:
- Use only if benefits outweigh risks; avoid high doses; prefer paracetamol or ibuprofen for mild pain.
- Serotonin Syndrome Warning:
- Symptoms appear within hours of adding a serotonergic drug to tramadol; discontinue tramadol and treat supportively if suspected.
- Opioid‑Safe Use:
- Encourage non‑opioid adjuncts (acetaminophen, NSAIDs, duloxetine) to reduce total opioid exposure.
- Non‑Pain Indications:
- Tramadol can treat neuropathic pain and osteoarthritis; dose adjustments may be required due to its norepinephrine reuptake inhibition.
- Drug Interaction Alert:
- Carbamazepine and phenytoin can *induce* tramadol metabolism → sub‑therapeutic analgesia.
- SSRIs can *potentiate* tramadol → ↑ respiratory depression risk.
- Clinical Scenario – Elderly:
- Start at the lowest dose (25 mg q6‑8 h) and titrate cautiously; monitor for falls and sedation.
- When to Escalate:
- If pain remains uncontrolled despite maximal doses, consider opioid rotation or multimodal analgesia rather than simply increasing tramadol dose.
--
• Ultram (tramadol) remains a versatile analgesic when used judiciously, with careful patient selection, dose titration, and monitoring to mitigate its unique pharmacologic and safety profile.